OJEMD  Vol.3 No.1 , February 2013
HFE Gene Mutation Associated with the Severity of Gestational Diabetes Mellitus in Belarusian Women
Abstract: To determine whether the H63D and C282Y mutations in HFE (hemochromatosis) gene are associated with the risk of gestational diabetes mellitus (GDM), we conducted the study of 65 incident cases. The class of gestational diabetes (A1, A2, B) in pregnant women was defined based on the results of glycemic profile and 75-g oral glucose tolerance test. Two single nucleotide polymorphisms (H63D and C282Y) in HFE gene were genotyped by PCR and RFLP (Restriction Fragment Length Polymorphism). The frequencies of mutations in patients cohort were: 0.14 for H63D and 0.02 for C282Y, which are similar to the data reported for Belarusian population (0.16 and 0.04 respectively). The detailed analysis of case subjects indicated association of H63D mutation with the severity of gestational diabetes mellitus. In the frequencies of H63D mutation and genotypes between the case subjects with A1 and B gestational diabetes were detected significant differences. Our data indicated that the presence of H63D mutation in pregnant women with GDM aggravates the disease—odds ratio 7.4 (95% CI 1.8 - 30.5). Women with gestational diabetes have severe increased risk for illness progressing to class B if they are H63D mutation carriers.
Cite this paper: L. Sivitskaya, N. Danilenko, Z. Zabarouskaya and O. Davydenko, "HFE Gene Mutation Associated with the Severity of Gestational Diabetes Mellitus in Belarusian Women," Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 1, 2013, pp. 13-17. doi: 10.4236/ojemd.2013.31002.

[1]   American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 32, Suppl. 1, 2009, pp. S62-S67. doi:10.2337/dc09-S062

[2]   American Diabetes Association, “Gestational of Diabetes Mellitus,” Diabetes Care, Vol. 27, Suppl. 1, 2004, pp. S88-S90. doi:10.2337/diacare.27.2007.S88

[3]   Z. V. Zabarouskaya, O. V. Muliarchik and T. A. Gdanova, “The Gestational Diabetes Mellitus Problems: The Main Aspects of the Pathogenesis, Clinical-Diagnostic Criteria, Principles of Treatments,” Medicinskie Novosti, No. 12, 2002, pp. 12-19.

[4]   M. Hod, “Textbook of Diabetes and Pregnancy,” 1st Edition, Martin Dunitz, London & New York, 2003.

[5]   P. Moleda, A. Binczak-Kuleta, K. Homa, K. Safranow, Z. Celewicz, A. Syrenicz, A. Stefanski, A. Fronczyk and L. Majikowska, “The Common C49620T Polymorphism in the Sulfonylurea Receptor Gene SUR (ABCC8) in Patients with Gestational Diabetes and Subsequent Glucose Metabolism Abnormalities,” Experimental Diabetes Researches, Published Online, 2012.

[6]   A. Papadopoulou , K. F. Lynch, N. Shaat, R. Hakansson, S. A. Ivarsson, K. Berntorp, C. D. Agardh and A. Lernmark, “Gestational Diabetes Mellitus Is Associated with TCF7L2 Gene Polymorphisms Independent of HLA-DQB1*0602 Genotypes and Islet Cell Autoantibodies,” Diabetic Medicine, Vol. 28, No. 9, 2011, pp. 1018-1027. doi:10.1111/j.1464-5491.2011.03359.x

[7]   H. R. Frigeri, I. C. Santos, R. R. Rea, A. C. Almeida, C. M. Fadel-Picheth, F. O. Pedrosa, E. M. Souza, F. G. Rego and G. Picheth, “Low Prevalence of Glucokinase Gene Mutations in Gestational Diabetic Patients with Good Glycemic Control,” Genetics and Molecular Researches, Vol. 11, No. 2, 2012, pp. 1433-1441. doi:10.4238/2012.May.18.2

[8]   I. C. Santos, D. R. Daga, H. R. Frigeri, R. R. Rea, A. C. Almeida, E. M. Souza, F. O. Pedrosa, C. M. Fadel-Picheth and G. Picheth, “The Functional Polymorphisms -429T>C and -374T>A of the RAGE Gene Promoter Are not Associated with Gestational Diabetes in Euro-Brazilians,” Genetics and Molecular Researches, Vol. 9, No. 2, 2010, pp. 1130-1135. doi:10.4238/vol9-2gmr817

[9]   K. Klein, P. Haslinger, D. Bancher-Todesca, H. Leipold, M. Kn?fler, A. Handisurya, A. Kautzky-Willer and C. Worda, “Transcription Factor 7-Like 2 Gene Polymorphisms and Gestational Diabetes Mellitus,” Journal of Maternal-Fetal and Neonatal Medicine, Vol. 25, No. 9, 2012, pp. 1783-1786. doi:10.3109/14767058.2012.663831

[10]   E. Causa, U. Hanusch-Enserer, M. Bischof, M. Spak, K. Kostner, A. Tammaa, A. Dunky and P. Ferenci, “Increased C282Y Heterosigosity in Gestational Diabetes,” Fetal Diagnosis and Therapy, Vol. 5, No. 5, 2005, pp. 349-354. doi:10.1159/000086811

[11]   L. Qi, J. Meigs, J. E. Manson, J. Ma, D. Hunter, N. Rifai and F. B. Hu, “HFE Genetic Variability, Body Iron Stores, and the Risk of Type 2 Diabetes in U.S. Women,” Diabetes, Vol. 54, No. 12, 2005, pp. 3567-3572. doi:10.2337/diabetes.54.12.3567

[12]   D. J. Halsall, I. McFarlane, J. Luan, T. M. Cox and N. J. Wareham, “Typical Type 2 Diabetes Mellitus and HFE Gene Mutations: A Population-Based Case-Control Study,” Human Molecular Genetics, Vol. 12, No. 12, 2003, pp. 1361-1365. doi:10.1093/hmg/ddg149

[13]   J. N. Feder, A. Gnirke, W. Thomas, Z. Tsuchihashi, D. A. Ruddy, A. Basava, F. Dormishian, R. Jr. Domingo, M. C. Ellis, A. Fullan, L. M. Hinton, N. L. Jones, B. E. Kimmel, G. S. Kronmal, P. Lauer, V. K. Lee, D. B. Loeb, F. A. Mapa, E. McClelland, N. C. Meyer, G. A. Mintier, N. Moeller, T. Moore, E. Morikang, C. E. Prass, L. Quintana, S. M. Starnes, R. C. Schatzman, K. J. Brunke, D. T. Drayna, N. J. Risch, B. R. Bacon and R. K. Wolff, “A Novel MHC Class I-Like Gene Is Mutated in Patients with Hereditary Hemochromatosis,” Nature Genetics, Vol. 13, No. 4, 1996, pp. 399-408. doi:10.1038/ng0896-399

[14]   J. M. Fernandes-Real, А. Lopes-Bermejo and W. Ricard, “Cross-Talk between Iron Metabolism and Diabetes,” Diabetes, Vol. 51, No. 8, 2002, pp. 2348-2354.

[15]   S. Swaminathan, V. A. Fonseca, M. G. Alam and S. V. Shah, “The Role of Iron in Diabetes and Its Complications,” Diabetes Care, Vol. 30, No. 7, 2007, pp. 1926-1933. doi:10.2337/dc06-2625

[16]   O. V. Muliarchik and Z. V. Zabarouskaya, “Diagnostic Features of Gestational Diabetes Mellitus and Treatment during Pregnancy,” Belarusian Medical Journal, No. 2, 2002, pp. 41-42.

[17]   L. N. Sivitskaya and A. I. Kushniarevich, “Hereditary Haemochromatosis: С282Y and H63D Mutations Frequencies of HFE Gene in Belarus Population,” Proceedings of the National Academy of Sciences of Belarus, Vol. 6, No 1, 2007, pp. 414-418.

[18]   C. C. Mathew, “The Isolation of High Molecular Weight Eucaryotic DNA,” In: J. M. Walker, Ed., Methods in Molecular Biology, Human Press, Clifton, 1984, pp. 31-34.

[19]   P. N. Babich, A. V. Chubenko and S. N. Lapach, “Application of Modern Statistical Methods in Clinical Trials. Part 3. Odds Ratio: Concept, Computation and Interpretation,” Ukrainian Medical Journal, Vol. 46, No. 2, 2004, pp. 138-144.

[20]   D. K. Moczulski, W. Grzeszczak and В. Gawlik, “Role of Hemochromatosis C282Y and H63D Mutations in HFE Gene in Development of Type 2 Diabetes and Diabetic Nephropathy,” Diabetes Care, Vol. 24, No. 7, 2001, pp. 1187-1191.

[21]   S. V. Mikhailova, O. V. Onopchenko, А. V. Sukhanov, V. N. Maksimov, Т. К. Gaskina, А. G. Romaschenko and М. I. Voevoda, “Haplotypic Analysis for the HFE Gene in Russian Populations and in Patients with Common Deseases,” Vestnik Vogis, Vol. 10. No. 3, 2006, pp. 504-513.

[22]   E. Ferrannini, “Insulin Resistance, Iron and Liver,” Lancet, Vol. 355, No. 9222, 2000, pp. 2181-2182. doi:10.1016/S0140-6736(00)02397-7

[23]   L. W. Oberley, “Free Radicals and Diabetes,” Free Radical Biology and Medicine, Vol. 5, No. 2, 1988, pp. 113-112. doi:10.1016/0891-5849(88)90036-6

[24]   Т. Т. Lao, P. L. Chan and K. F. Tam, “Gestational Diabetes Mellitus in the Last Trimester—A Feature of Maternal Iron Excess,” Diabetic Medicine, Vol. 18, No. 3, 2001, pp. 218-223.

[25]   G. Dorner, A. Plagemann and H. Reinagel, “Familial Diabetes Aggregation in Type I Diabetics: Gestational Diabetes an Apparent Risk Factor for Increased Diabetes Susceptibility in the Offspring,” Experimental and Clinical Endocrinology and Diabetes, Vol. 89, No. 1, 1987, pp. 84-90. doi:10.1055/s-0029-1210631

[26]   P. Damm, “Future Risk of Diabetes in Mother and Child after Gestational Diabetes Mellitus,” International Journal of Gynecology and Obstetrics, Vol. 104, Suppl. 1, 2009, pp. S25-S26.